Company Filing History:
Years Active: 2025
Title: Jean-Philippe Jelin: Innovator in Cardiac Treatment
Introduction
Jean-Philippe Jelin is a notable inventor based in Montpellier, France. He has made significant contributions to the field of cardiac treatment through his innovative research and development. His work focuses on novel polymorphic forms of a specific compound that has potential therapeutic applications.
Latest Patents
Jean-Philippe Jelin holds a patent for the polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide. This invention provides novel polymorphs that are useful for treating various cardiac disorders, including systolic dysfunction, dilated cardiomyopathy (DCM), and heart failure with preserved ejection fraction (HFrEF). The patent details the synthesis and characterization of these polymorphs, as well as methods for treating heart disease.
Career Highlights
Jean-Philippe Jelin is associated with Myokardia, Inc., a company dedicated to advancing therapies for heart disease. His work has been instrumental in developing treatments that address critical cardiac conditions. He has a strong focus on improving patient outcomes through innovative solutions.
Collaborations
Throughout his career, Jean-Philippe has collaborated with notable colleagues, including Min Zhong and Olivier Monnier. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
Jean-Philippe Jelin is a prominent inventor whose work in cardiac treatment showcases the importance of innovation in medicine. His contributions through patents and collaborations highlight his commitment to improving healthcare outcomes for patients with heart conditions.